MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Advanced Breast Cancer Therapies
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

898 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
898 works in the cohort · of 4,299,418page 11 of 18

Labels cover 3 of 898 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 898 of 898 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affaboutunlabeled
Safety results of the Canadian Expanded Access Program (EAP) of palbociclib (PAL) plus letrozole (L) in postmenopausal patients (pts) with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) deemed appropriate candidates for first-line (1L) endocrine therapy (ET) with L.
Anil A. Joy, Shailendra Verma, Louise Provencher, Kathy Puyana Theall, Dongrui R. Lu, Florence Dequen +1 more
2017· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
1
citations
affunlabeled
Abstract PS10-14: Efficacy and safety of palbociclib (PAL) in patients (pts) with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) with preexisting conditions: A post hoc analysis of PALOMA-2
Karen Gelmon, Janice M. Walshe, Reshma Mahtani, Anil A. Joy, Meghan Karuturi, Patrick Neven +5 more
2021· article· en· Cancer Research· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
1
citations
affunlabeled
Correlation between work productivity loss (WPL) and European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) domains from the MONALEESA-7 (ML-7) trial of premenopausal women with HR+/HER2- advanced breast cancer (ABC).
Debu Tripathy, Tristan Curteis, Sara A. Hurvitz, Denise A. Yardley, Fábio Franke, Govind Babu Kanakasetty +7 more
2021· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · noneconsensus · none
1
citations
aboutno affunlabeled
Abstract OT3-05-04: A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA)
Sibylle Loibl, Jana Barinoff, Sabine Seiler, Thomas Decker, Carsten Denkert, A-C. Hardy-Bessard +13 more
2018· article· en· Cancer Research· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
1
citations
affno abstractunlabeled
309P Real-world effectiveness of alpelisib (ALP) + fulvestrant (FUL) compared with standard treatment among patients (Pts) with hormone-receptor positive (HR+) human epidermal growth factor receptor-2 negative (HER2–) PIK3CA-mutated (Mut) advanced breast cancer (ABC)
Simon Turner, Stephen Chia, Hemanth Kanakamedala, W-C. Hsu, J. Park, David Chandiwana +4 more
2020· article· en· Annals of Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
1
citations
affunlabeled
Abstract P1-19-10: Safety and efficacy of abemaciclib plus endocrine therapy (ET) in elderly patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+, HER2-) advanced breast cancer: An age-specific subgroup analysis of MONARCH 2 and 3 trials
Matthew P. Goetz, Meena Okera, Hans Wildiers, Mario Campone, Eva‐Maria Grischke, Luís Manso +5 more
2020· article· en· Cancer Research· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
1
citations
affno abstractunlabeled
281P Cyclin-dependent kinase 4/6 inhibitors combined with endocrine therapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: A meta-analysis of randomized clinical trials
V.F.C. Alves, Francisco Cézar Aquino de Moraes, Gabriel Gomes, Gustavo de Oliveira Almeida, Sarah Vitória Bristot Carnevalli, Jonathan N. Priantti +3 more
2023· article· en· Annals of Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
1
citations
affunlabeled
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
Laurence Buisseret, Delphine Loirat, Philippe Aftimos, Christian Maurer, Kevin Punie, Véronique Debien +30 more
2023· erratum· en· Nature Communications· Medicine
distilled prediction:candidate · metaepi_narrow+sts+research_integrityconsensus · none
1
citations
aboutno affunlabeled
2024 CASEM Poster Abstracts
2024· article· en· Clinical Journal of Sport Medicine· Medicine
distilled prediction:candidate · insufficient_payloadconsensus · none
1
citations
venueno affno abstractunlabeled
Biomarker Research in World Journal of Oncology
Kazuaki Takabe, Matthew G.K. Benesch
2023· editorial· en· World Journal of Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrityconsensus · none
1
citations
← previousnext →

How this was built: Screen · Findings · About